Caribou Biosciences to Participate in Upcoming Investor Conferences
02 5월 2024 - 5:05AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
the company’s participation in the following investor conferences:
- 2024 RBC Capital Markets Global Healthcare
Conference, New York, NYMay 14, 2024, fireside chat at
3:35 pm EDTWebcast
- BofA Securities 2024 Health Care Conference,
Las Vegas, NVMay 15, 2024, corporate presentation at 3:40 pm
PDTWebcast
For more information, including available webcasts, visit the
Events page on Caribou’s website. Webcasts will be available on the
Caribou website for 30 days after the event.
About Caribou’s novel next-generation CRISPR
platformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve activity against diseases. Caribou
is advancing a pipeline of off-the-shelf cell therapies from its
CAR-T cell platform as readily available treatments for patients
with hematologic malignancies and autoimmune diseases. Follow us
@CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc.
contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald, PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Caribou Biosciences (NASDAQ:CRBU)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024